原料药 API

A cornerstone SGLT2 inhibitor spanning diabetes, heart failure and CKD (triple indication) with substantial global demand; GMP/DMF-ready and ideal for driving API sourcing through finished-dose registration.

A first-in-class CMV terminase inhibitor replacing older ganciclovir-class agents with a better safety profile; a niche, high-value specialty API with limited competition.

A novel single-oral-dose influenza agent with concentrated seasonal demand; integrated API-to-finished supply is attractive for regional pandemic stockpiling.

The first nonsteroidal mineralocorticoid receptor antagonist (nsMRA), filling an anti-inflammatory and anti-fibrotic gap in diabetic kidney disease and recommended by major guidelines, a clearly incremental new product.

A core endocrine therapy for prostate cancer requiring continuous long-term dosing, ensuring stable annual API demand and well suited to long-term FSO supply arrangements.

A foundational agent in myelofibrosis with continued dermatology indication expansion; long-marketed with rigid, predictable demand, a low-volatility steady product.

A leading oral targeted therapy in autoimmunity spanning rheumatology, dermatology and gastroenterology, with strong and definable volume upside.

A topical non-fluoroquinolone quinolone targeting resistant Gram-positive bacteria; its pediatric and local-use profile offers differentiation in OTC and pediatric markets.

Glaucoma requires lifelong therapy, sustaining steady demand for ophthalmic API; frequently combined with beta-blockers, enabling fixed-dose combination registration.

The preferred dental local anesthetic, fast-acting and highly diffusive, with consumption tied to global dental visits, a high-frequency consumable API.

A long-acting local anesthetic for enhanced-recovery (ERAS) pathways with lower cardiotoxicity than bupivacaine; growth in day-surgery directly lifts volume.

The world's first approved MASH therapy, opening a vast untreated blue-ocean; numerous follow-on pipelines will scale API demand alongside the entire class.

A next-generation potassium-competitive acid blocker (P-CAB) with faster onset and no food effect versus PPIs, the upgrade direction for acid-related disease.

A next-generation oral anticoagulant (DOAC) clearly replacing warfarin, with a huge atrial-fibrillation population on chronic therapy, a clearly definable blockbuster.

A non-sedating second-generation antihistamine with seasonal demand and long-term use; suitable for combination with cold remedies and pediatric syrups.

The most consequential molecule in the GLP-1 class, dual-driven by diabetes and obesity with demand far exceeding capacity; a high-barrier peptide API and our top strategic product.

The first approved non-hormonal therapy for menopausal hot flashes, with broad scope to replace hormone therapy, a large and long-unmet patient population.

A mainstream pet parasiticide with single-dose long protection; rising global pet-care spending sustains growing animal-health API demand.

A core oral pet parasiticide with good palatability and monthly dosing, often combined with milbemycin oxime, enabling fixed-combination product lines.

The only isoxazoline expanded into human ophthalmology (demodex blepharitis), combining a steady animal-health base with a human-use upside option.

One of several same-class agents, suitable as a combination supply within an animal-health portfolio to meet customers' generic and differentiated sourcing needs.

The first marketed P-CAB with stronger, more durable acid suppression and markedly higher H. pylori eradication; especially sizable demand in high-H. pylori Asian markets.

The first oral complement-factor-B inhibitor, converting PNH from infusion to oral therapy and expanding into nephrology, a high-value rare-disease molecule.

Addresses high-unmet need in post-transplant GVHD with a clear mechanism and limited competition, well suited to registration partnerships with transplant centers.